Pages that link to "Q52872238"
Jump to navigation
Jump to search
The following pages link to First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. (Q52872238):
Displaying 50 items.
- Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma (Q26744830) (← links)
- Exosome-mediated small RNA delivery for gene therapy (Q26747740) (← links)
- siRNA Versus miRNA as Therapeutics for Gene Silencing (Q26786876) (← links)
- Nanotechnology: Future of Oncotherapy (Q26801067) (← links)
- Knocking down disease: a progress report on siRNA therapeutics (Q28082939) (← links)
- Switchable Lipids: Conformational Change for Fast pH-Triggered Cytoplasmic Delivery (Q34485756) (← links)
- Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer (Q34537580) (← links)
- Multifunctional Nanoparticles Facilitate Molecular Targeting and miRNA Delivery to Inhibit Atherosclerosis in ApoE(-/-) Mice (Q36089057) (← links)
- Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment (Q36784555) (← links)
- Effective Small Interfering RNA Therapy to Treat CLCN7-dependent Autosomal Dominant Osteopetrosis Type 2. (Q36928118) (← links)
- Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4. (Q37654522) (← links)
- Clinical experiences with systemically administered siRNA-based therapeutics in cancer (Q38633261) (← links)
- Recent advances in siRNA delivery (Q38648525) (← links)
- Mathematical Modeling: A Tool for Optimization of Lipid Nanoparticle-Mediated Delivery of siRNA. (Q38669909) (← links)
- Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines (Q38674444) (← links)
- Imaging-guided delivery of RNAi for anticancer treatment (Q38710046) (← links)
- Strategies to optimize siRNA delivery to hepatocellular carcinoma cells. (Q38713376) (← links)
- Insight into the relationship between the cell culture model, cell trafficking and siRNA silencing efficiency. (Q38761503) (← links)
- Nanomedicines for renal disease: current status and future applications (Q38802375) (← links)
- Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy. (Q38871344) (← links)
- Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). (Q38926178) (← links)
- Translating pharmacodynamic biomarkers from bench to bedside: analytical validation and fit-for-purpose studies to qualify multiplex immunofluorescent assays for use on clinical core biopsy specimens (Q38963126) (← links)
- Biomaterials in siRNA Delivery: A Comprehensive Review (Q38971775) (← links)
- Cancer nanomedicine: progress, challenges and opportunities (Q39005226) (← links)
- Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles (Q39113994) (← links)
- Emerging protein kinase inhibitors for treating pancreatic cancer (Q39158411) (← links)
- The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market (Q39227810) (← links)
- Combination of RNA Interference and Stem Cells for Treatment of Central Nervous System Diseases (Q39290532) (← links)
- MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia? (Q39324079) (← links)
- Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine (Q41696168) (← links)
- Novel targeted therapy for neuroblastoma: silencing the MXD3 gene using siRNA. (Q46197587) (← links)
- Oligonucleotide-based pharmaceuticals: Non-clinical and clinical safety signals and non-clinical testing strategies (Q46297631) (← links)
- Gankyrin: a novel promising therapeutic target for hepatocellular carcinoma (Q47661011) (← links)
- Nanotechnology as a Delivery Tool for Precision Cancer Therapies (Q50091869) (← links)
- Engineering functional inorganic-organic hybrid systems: advances in siRNA therapeutics. (Q50123721) (← links)
- Applying nanotherapeutics to improve chemoradiotherapy treatment for cancer (Q50499549) (← links)
- Role of Gene Therapy in Pancreatic Cancer-A Review. (Q52610258) (← links)
- Endogenous Control Mechanisms of FAK and PYK2 and Their Relevance to Cancer Development. (Q54976490) (← links)
- Nanoparticles in the clinic. (Q55003489) (← links)
- Latest development on RNA-based drugs and vaccines. (Q55231576) (← links)
- Deciphering Non-coding RNAs in Cardiovascular Health and Disease. (Q55668859) (← links)
- Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics (Q57282212) (← links)
- Engineering Nanoparticles for Targeted Delivery of Nucleic Acid Therapeutics in Tumor (Q58552610) (← links)
- Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes (Q59133785) (← links)
- Application of Locked Nucleic Acid Oligonucleotides for siRNA Preclinical Bioanalytics (Q64065405) (← links)
- Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach (Q64070969) (← links)
- Oncogenic Signaling in Tumorigenesis and Applications of siRNA Nanotherapeutics in Breast Cancer. (Q64955344) (← links)
- Clinical cancer nanomedicine (Q65556503) (← links)
- Topical Lyophilized Targeted Lipid Nanoparticles in the Restoration of Skin Barrier Function following Burn Wound (Q88866376) (← links)
- Interrogation of nonconserved human adipose lincRNAs identifies a regulatory role of linc-ADAL in adipocyte metabolism (Q89169915) (← links)